



Published in final edited form as:

Cancer Res. 2009 May 1; 69(9): 3955–3962. doi:10.1158/0008-5472.CAN-08-4450.

PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor positive breast cancer

Robert J. Crowder¹, Chanpheng Phommaly¹, Yu Tao², Jeremy Hoog¹, Jingqin Luo², Charles M. Perou³, Joel S. Parker³, Melinda A. Miller⁴, David G. Huntsman⁴, Li Lin¹, Jacqueline Snider¹, Sherri R. Davies¹, John A. Olson Jr.⁵, Mark A. Watson^{6,7}, Anthony Saporita¹, Jason D. Weber^{1,7}, and Matthew J. Ellis^{1,7,*}

¹Division of Oncology, Department of Medicine, Washington University in St Louis, MO, USA

²Department of Biostatistics, Washington University in St Louis, MO, USA

³Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA

⁴Center for Translational and Applied Genomics, and the British Columbia Cancer Agency, Vancouver, British Columbia, Canada

⁵Duke Comprehensive Cancer Center, Durham NC, USA

⁶Department of Pathology and Immunology, Washington University School of Medicine, St. Louis MO USA

⁷Siteman Comprehensive Cancer Center, St. Louis MO USA

Abstract

Several phosphoinositide-3-kinase (PI3K) catalytic subunit inhibitors are currently in clinical trial. We therefore sought to examine relationships between pharmacological inhibition and somatic mutations in PI3K catalytic subunits in ER+ breast cancer, where these mutations are particularly common. RNA interference (RNAi) was used to determine the effect of selective inhibition of PI3K catalytic subunits, p110 α and p110 β , in ER+ breast cancer cells harboring either mutation (*PIK3CA*) or gene amplification (*PIK3CB*). p110 α RNAi inhibited growth and promoted apoptosis in all tested ER+ breast cancer cells under estrogen deprived-conditions, whereas p110 β RNAi only affected cells harboring *PIK3CB* amplification. Moreover, dual p110 α /p110 β inhibition potentiated these effects. In addition, treatment with the clinical grade PI3K catalytic subunit inhibitor BEZ235 also promoted apoptosis in ER+ breast cancer cells. Importantly, estradiol suppressed apoptosis induced by both gene knockdowns and by BEZ235 treatment. Our results suggest that PI3K inhibitors should target both p110 α and p110 β catalytic subunits, whether wild-type or mutant, and be combined with endocrine therapy for maximal efficacy when treating ER+ breast cancer.

Keywords

breast cancer; estrogen receptor; PI3 kinase; endocrine therapy; synthetic lethality

Requests for Reprints: Matthew J. Ellis, Department of Medicine, Washington University School of Medicine, 660 South Euclid Ave, Box 8069, St Louis, MO 63110, USA. mellis@dom.wustl.edu.

Conflicts of Interest: No pharmaceutical company funding was received for this research project. Dr Ellis has received honoraria, grants and has served as a consultant for AstraZenica, Novartis and Pfizer.

INTRODUCTION

Despite the use of adjuvant endocrine treatment prognosis remains poor for a significant population of patients with estrogen receptor positive (ER+) breast cancer (1). The cellular basis for the efficacy of endocrine therapy treatment is principally through inhibitory effects on the tumor cell cycle (2) because, unlike cytotoxic chemotherapy, it has never been clearly demonstrated that endocrine therapy promotes cell death through apoptosis (3). A logical approach to improving ER+ breast cancer treatment is, therefore, to inhibit gene activities that promote survival in the presence of ER targeting agents. To address this hypothesis we focused on combining endocrine agents with inhibitors of phosphoinositide 3-kinase (PI3K) because this pathway promotes cell survival in a number of tumor types (4).

Aberrant activation of the PI3K pathway through mutation and epigenetic silencing of genes within the PI3K signaling cascade frequently occurs in breast cancer. Gain of function mutations in the PI3K alpha catalytic subunit (*PIK3CA*) occur in ~30% of ER+ breast cancer and, much less commonly, activating *AKT1* mutations. Loss of function mutations affect the PI3K negative regulator *PTEN* and gene amplification in S6 protein kinase-1 (*RPS6KB1*) and *AKT2* have also been reported (5–8). Whereas the precise consequences of these aberrations on the clinical outcome of ER+ disease remain to be fully defined, *RPS6KB1* amplification and *PTEN* loss are both associated with poor prognosis and *PTEN* loss may correlate with endocrine therapy resistance in ER+ tumors (9–15). In contrast, *PIK3CA* presents a more complex picture and mutations may differentially impact prognosis depending upon the affected *PIK3CA* functional domain (15). Finally, a role for *PIK3CB*, the gene encoding the PI3K beta catalytic subunit, has also recently been postulated in breast cancer, although mutations in this gene have not been detected (16,17).

Several PI3K catalytic subunit inhibitors are advancing towards Phase II clinical testing (18). The targets for these agents are the products of the Class 1A PI3K catalytic subunit genes (*PIK3CA*, *PIK3CB* and *PIK3CD*). *PIK3CA* and *PIK3CB* are believed to be broadly expressed in breast cancer, whereas *PIK3CD* gene expression is more limited (19). We sought to address a number of issues related to the clinical development of these compounds. First, it is not clear if *PIK3CA* mutation status restricts the efficacy of PI3K inhibitors. Second, catalytic subunit targeting strategies for achieving maximum therapeutic effect have not been developed. Finally, a rationale for the combination of a PI3K inhibitor and endocrine therapy in ER+ breast cancer has not been established.

MATERIALS AND METHODS

Human Tumor Samples

Fresh-frozen and formalin-fixed paraffin embedded (FFPE) human breast tumor biopsies for paired aCGH and *PIK3CB* fluorescence in situ hybridization (FISH) were obtained from ER+ breast cancer patients undergoing preoperative letrozole treatment (POL) (20). RNA for transcriptional profiling and cDNA synthesis (samples \geq 50% tumor) and DNA for aCGH (samples \geq 70% tumor cellularity) were prepared from sectioned fresh-frozen samples using RNeasy Mini and QIAamp DNA Micro kits (Qiagen, Valencia, CA) for RNA and DNA extractions. Tumor enrichment was performed using macrodissection or an Arcturus Veritas laser capture microdissection instrument (Arcturus Bioscience, Mountain View, CA). A human breast tissue microarray (TMA) obtained at the Siteman Cancer Center Tissue Core Facility and used for *PIK3CB* FISH was described previously (21).

aCGH

Details are provided in Supplementary Materials and Methods.

Transcriptional Profiling

Details are provided in Supplementary Materials and Methods.

Gene Re-sequencing

Details for *PIK3CA* and *PIK3CB* re-sequencing are provided in Supplementary Materials and Methods.

Cell Culture

The HCC712 cell line (22) was provided by Dr. Adi Gazdar. Other cell lines were obtained from ATCC (Manassas, VA). Cell lines were propagated in RPMI 1640 containing 10% FBS with antibiotics and supplements (50 μ g/mL gentamycin, pyruvate, 10 mM Hepes and glucose to 4.5 g/L) in a humidified 37°C incubator containing 5% CO₂. To test the effects of estradiol (E₂, Sigma-Aldrich) treatment and withdrawal, cells were maintained in phenol red-free RPMI 1640 containing 5% charcoal-stripped serum (CSS, Invitrogen, Carlsbad, CA) (CSS medium) for at least 7 days prior to siRNA transfection or drug treatments.

Protein Extracts

Details are provided in Supplementary Materials and Methods.

RNAi Transfection

Nuclease-resistant Stealth duplex siRNAs (Invitrogen) were used for RNAi experiments. The following siRNAs were used: Universal Low GC Negative Control; *PIK3CA* siRNAs (target sequence 5'-GGUGGUGCGAAUUCUCACACUAU-3' for primary siRNA duplex and 5'-CCCAAGAAUCCUAGUAGAAUGUUUA-3' for alternative siRNA duplex); *PIK3CB* siRNAs (target sequence 5'-GCUGUCAAUCAAGUGGAAUAAACUU-3' for primary siRNA duplex and 5'-GCGCUUGAUGGAUUUACUCUGGAAA-3' for alternative siRNA duplex). *PIK3CA* and *PIK3CB* siRNA knockdown efficiencies were determined by reverse transfection of siRNAs into cells and immunoblotting cell lysates prepared three days after transfection. Maximal knockdown efficiency (>70%) was achieved with 10 nM *PIK3CA* or *PIK3CB* siRNA. Transfection efficiency assessed by the BLOCK-IT fluorescent oligo (Invitrogen) was >90% in all cell lines.

Immunoblotting

Details are provided in Supplementary Materials and Methods.

Cell Growth Assay

Details are provided in Supplementary Materials and Methods.

Cell Death Assay

Details are provided in Supplementary Materials and Methods.

PIK3CB FISH

Details are provided in Supplementary Materials and Methods.

Statistical Analysis

Unless indicated otherwise, quantitative data are presented as mean \pm SEM. The effect of siRNA knockdowns and pharmacologic treatments on cell growth and apoptosis was analyzed using ANOVA. If within group comparisons reached statistical significance ($p < 0.05$), comparisons between specific treatments were made with Student's *t* test. Interactions between

PAM50 subtypes or *PIK3CA* mutation status and *PIK3CA*, *PIK3CB* and *PIK3CD* expression were analyzed by t-tests using the SAS version 9.1 Statistical Package (SAS Institute Inc., Cary, NC).

RESULTS

p110 α and p110 β Expression in Breast Cancer Cells

The expression of p110 α and p110 β was examined in breast cancer cell lines by western blot analysis (Figure 1A). The panel included ER+ breast cancer cells with activating *PIK3CA* mutations (MCF-7 and T47D) or wild-type *PIK3CA* (HCC712) (11). Both PI3K catalytic subunit isoforms were ubiquitously present, however p110 α and p110 β expression varied widely. Notably, p110 β protein expression was higher in ER+ cells with the HCC712 cell line (22) expressing the most. To determine if increased expression was associated with gene copy gain, high resolution array comparative genomic hybridization (aCGH) was performed. This analysis revealed *PIK3CB* copy gain at 3q22.3 in the HCC712 cell line, but not in other cell lines (Figure 1B). *PIK3CB* gene copy number in HCC712 cells was confirmed by fluorescent in situ hybridization (FISH) (gene to centromere ratio ~2.5).

PIK3CB Amplification in Primary Breast Cancer

Array CGH analysis on ER+ primary breast tumors revealed *PIK3CB* copy gain in at least one tumor examined (1/35) which was confirmed by FISH (amplification ration 2.3, Figure 1C). In another series of primary breast cancer samples from a breast tissue microarray, low-level *PIK3CB* amplification or copy number gain was observed by FISH in different breast cancer subtypes (1 ER-, 1 ER+, 2 ER+/HER2+), suggesting that *PIK3CB* copy number gain occurs with an incidence of ~5% (Supplementary Table1). To determine if *PIK3CB* was mutant, the *PIK3CB* helical and kinase domains in 22 primary ER+ breast tumors were sequenced, including the *PIK3CB* amplified breast tumor illustrated in Figure 1C and three breast cancer cell lines (HCC712, MCF-7 and T47D). No sequence anomalies were detected.

PIK3CA and *PIK3CB* Are Expressed at Higher Levels in Luminal B Breast Cancer in Comparison to Luminal A Breast Cancer

The variation in *PIK3CA* and *PIK3CB* expression observed in breast cancer cell lines led to an expression analysis in a series of ER+ primary breast cancers. First, microarray studies were examined using the PAM50 model (23) in order to subtype cases into Luminal A (good prognosis - 31 cases) or Luminal B (poor prognosis - 44 cases (Table 1). There was strong evidence for higher expression of both *PIK3CA* and *PIK3CB* in poor prognosis Luminal B tumors when compared to Luminal A tumors. Higher expression of *PIK3CD* was also observed in Luminal B tumors but the result was less striking. The presence of a *PIK3CA* mutation was associated with higher levels of *PIK3CA* mRNA but not *PIK3CB* or *PIK3CD*.

p110 α is the Predominant Mediator of PI3K signaling in Breast Cancer Cells but p110 β Contributes in a Cell Line Restricted Manner

To determine the individual effects of *PIK3CA* and *PIK3CB* on PI3K signaling, small interfering (si)RNAs were used to selectively knock down p110 α and p110 β expression (Figure 2A). An analysis of signal transduction demonstrated that *PIK3CB* RNAi had no effect on serum-stimulated AKT phosphorylation in MCF-7, T47D and MDA-MB-231 cells, but partially inhibited Akt phosphorylation in HCC712 cells (Figure 2A). Knockdown of p110 β had no clear effect on serum-stimulated phosphorylation of S6 protein in any of the cell lines tested. In contrast, *PIK3CA* RNAi suppressed serum-stimulated Akt phosphorylation in all cell lines tested. S6 phosphorylation was also significantly inhibited in MCF-7 and T47D cells but not in the HCC712 and MDA-MB-231 cell lines. Consistent with previous studies (24), we

observed reductions in Akt and S6 protein levels in some experiments, particularly for MCF-7 cells. To test whether the lack of inhibition of serum-stimulated S6 phosphorylation by p110 α knockdown in MDA-MB-231 and HCC712 cells was due to compensatory signaling through p110 β , dual p110 α /p110 β knockdowns were performed (Figure 2B). Combined p110 α /p110 β knockdown had no clear effect on S6 phosphorylation in MDA-MB-231 cells. However the combination partially inhibited S6 phosphorylation in HCC712 cells indicating that both PIK3CA and PIK3CB must be inhibited to impact S6 kinase activation in this cell line. Overall, this analysis indicated that p110 α is the major catalytic subunit that transduces PI3K pathway signals in ER+ breast cancer cells, but p110 β significantly contributes to pathway activation, particularly in cells containing higher levels of p110 β expression.

PIK3CA and PIK3CB RNAi Inhibit ER+ Breast Cancer Cell Growth and Survival

To more precisely determine the cellular response of ER+ cells, the effects of RNAi mediated p110 α and p110 β inhibition were examined under estrogen-dependent growth conditions (Figure 3A). *PIK3CA* RNAi inhibited growth in all cell lines, ranging from a modest reduction in growth in the MDA-MB-231 cell line to a greater than 90% reduction in MCF-7 cells. In contrast, *PIK3CB* RNAi inhibited growth only in HCC712 cells. To determine if *PIK3CA* and *PIK3CB* RNAi promoted cell death, apoptosis was quantified in the presence and absence of estradiol (Figure 3B). Estrogen deprivation alone resulted in no significant increase in cell death in HCC712 and T47D cells but a modest (significant) increase in cell death in MCF-7 cells. However, *PIK3CA* RNAi resulted in significant activation of apoptosis in estrogen-deprived MCF-7, T47D and HCC712 cells. In particular, p110 α knockdown dramatically induced cell death in estrogen-deprived MCF-7 cells, with approximately 50% of cells dying via apoptosis seven days after transfection (Figure 3B). Consistent with data on cell growth, *PIK3CB* RNAi promoted apoptosis in HCC712 cells but not in the other cell lines examined. In contrast to the effects on ER+ cells, neither *PIK3CA* nor *PIK3CB* RNAi affected the survival of ER- MDA-MB-231 cells. Importantly, estradiol treatment suppressed the induction of apoptosis by *PIK3CB* RNAi in HCC712 cells and *PIK3CA* RNAi in all three ER+ cell lines, indicating that the combination of estrogen deprivation with specific PI3K inhibition caused synthetic lethality.

Combined PIK3CA/PIK3CB RNAi Enhances Apoptosis in Estrogen-deprived ER+ Breast Cancer Cells Compared to Either Single Gene Knockdown

Next, we examined the effects of simultaneous inhibition of *PIK3CA* and *PIK3CB* on cell growth and survival using RNAi (Figure 4A, B). Dual knockdown of p110 α and p110 β reduced cell growth by ~90% in estrogen-deprived MCF-7 cells, similar to the inhibition of cell growth caused by p110 α knockdown alone (Figure 4A). In contrast, dual p110 α /p110 β knockdowns produced a greater reduction in cell growth in estrogen-deprived T47D cells (90% inhibition of cell growth) in comparison to the single subunit knockdowns (65% growth inhibition for *PIK3CA* RNAi, no significant growth inhibition for *PIK3CB* RNAi). Combined RNAi was also effective in inhibiting HCC712 cell growth; however the growth of ER- MDA-MB-231 cells was unaffected. While dual p110 α /p110 β knockdown did not enhance cell death in estrogen-deprived MCF-7 cells compared to the marked effect already achieved by p110 α knockdown alone, combined p110 α /p110 β knockdown resulted in approximately 4-fold higher levels of apoptosis in T47D and HCC712, similar to that achieved in MCF7 cells with single *PIK3CA* knockdown. In contrast, the survival of MDA-MB-231 cells was unaffected by dual p110 α /p110 β knockdown (Figure 4B). Importantly, estradiol treatment significantly rescued all three ER+ cell lines from cell death caused by dual p110 α /p110 β knockdown. It remained possible that the induction of apoptosis observed with RNAi knockdown was caused by off-target siRNA effects and that rescue of apoptosis with estradiol is not ER-dependent. However, dual p110 α /p110 β knockdowns in T47D cells with different siRNA than those used in Figure 3A, 3B, Figure 4A and 4B also induced apoptosis in estrogen-deprived cells. In addition,

treatment with the ER-specific inhibitor fulvestrant abrogated rescue by estradiol indicating that estradiol rescue was mediated by the ER (Figure 4C).

BEZ235 Induces Apoptosis in Estrogen-Deprived ER+ Breast Cancer Cells

The PIK3CA and PIK3CB RNAi experiments in the cell line panel provide a defined system for examining the potential of pharmacological PI3K inhibitors in breast cancer cells. The effects of BEZ235 (a dual PI3K Class 1 catalytic subunit/mTOR inhibitor) was therefore investigated. BEZ235 has been shown to potently inhibit wild-type and mutant p110 α at low nanomolar concentrations (IC₅₀ ~ 5nM) and p110 β at significantly higher concentrations (IC₅₀ ~ 75 nM) (25). Signaling effects in the cell line panel are consistent with a selective p110 α inhibitor (summarized in Figure 5A). Low concentrations (5nM) of BEZ235 significantly inhibited the growth of all three ER+ breast cancer cell lines both in the presence and absence of estrogen (Figure 5B). In contrast, only high concentrations (50 nM) of BEZ235 inhibited MDA-MB-231 cell growth. When the effect of BEZ235 on cell survival in the presence and absence of estrogen was examined, marked differences between the three ER+ cell lines emerged (Figure 5C). Treatment of estrogen-deprived MCF-7 and T47D cells with concentrations of BEZ235 as low as 5 nM promoted cell death. However, effect of BEZ235 on survival was maximal using 5 nM BEZ235 in T47D cells. In contrast, the level of apoptosis in MCF-7 cells increased with BEZ235 concentration and approached the levels observed with PIK3CA RNAi at 50nM. In estradiol rescue experiments, induction of cell death by 5 nM BEZ235 in MCF7 cells was completely blocked by estradiol and in the presence of estradiol four-fold higher doses \geq 20 nM were required to induce cell death. Remarkably, estradiol abrogated the BEZ235-induced cell death in T47D cells at all doses tested. HCC712 cells were the least sensitive to BEZ235 treatment and required higher concentrations (\geq 20 nM) to promote cell death under estrogen-deprived conditions. However, estrogen did suppress BEZ235-induced apoptosis in HCC712 cells such that cell death only occurred in estradiol treated cells at the highest concentration tested (50nM). Consistent with the PIK3CA and PIK3CB single and combination knockdown results, BEZ235 treatment did not induce apoptosis in MDA-MB-231 cells.

DISCUSSION

The role of estrogen in the proliferation of ER+ breast tumors is well established. However, the role of estrogen as a survival factor is less clear. Preclinical studies with the MCF-7 cell line demonstrated that treatment with antiestrogens or estrogen deprivation increases apoptosis, as we can confirm (26–28). However, MCF-7 cells are unusual in this regard since we did not observe estrogen-deprivation induced apoptosis in the HCC712 or T47D cell lines and in the neoadjuvant endocrine therapy setting, treatment did not increase apoptosis (3,29). Our data indicates that signaling through the PI3K pathway may explain these observations since estradiol promotes survival only when PI3K is inhibited. The presence of two apparently independent cell survival mechanisms, one PI3K dependent and one estradiol dependent, creates an opportunity for synthetic lethality. At the current time it is not known whether estrogen promotes survival through ER-dependent transcription or by rapid, non-genomic activation of signal transduction pathways (30,31). Nevertheless, our data strongly suggest that the effectiveness of PI3K catalytic subunit inhibitors in treating ER+ breast cancer will be greatest when combined with endocrine therapy.

In vitro studies have demonstrated that activated forms of p110 α or p110 β transform mammary epithelium (32,33). Knock-in and knock-out transgenic mouse studies confirmed these findings and p110 β appears to be particularly important for ERBB2-driven breast cancer (16,34) and in the promotion of proliferation, survival and invasiveness in a variety of cancer types (35–37). The data presented in this study is the first to demonstrate PIK3CB amplification in primary

breast cancer and suggests that this amplification event may promote oncogenesis. Our initial screen indicates *PIK3CB* copy number gain occurs at a low frequency (~5%) in tumors of breast cancer patients, however this may be clinically significant, since breast cancer is common (38). We also find that *PIK3CB* is preferentially expressed in Luminal B breast cancer regardless of gene copy number, indicating that this isoform is a potentially important therapeutic target, perhaps as a conduit for the effects of other somatic mutations that activate the PI3K such as *PTEN* loss (17). Interestingly, our *in vitro* data indicates that *PIK3CB* supports cell survival in HCC712 cells under estrogen deprived conditions, implying that targeted p110 β inhibition could be effective in treating *PIK3CB*-amplified breast tumors. However our data also suggests that both *PIK3CA* and *PIK3CB* may have to be inhibited under these circumstances since high level apoptosis only occurred when both catalytic subunits were targeted. Since *PIK3CA* is wild-type in HCC712 cells we also conclude that *PIK3CA* gain of function mutations are not a prerequisite for the synthetic lethal effect when combining estrogen deprivation and PI3K inhibition. Additionally, inhibition of p110 β also appears relevant in the presence of a *PIK3CA* mutation. T47D cells express modest levels of wild-type p110 β as well as a mutant *PIK3CA*, raising the question of whether *PIK3CB* provides an escape from mutant p110 α inhibition. A comparison between single and combined knockdowns suggests that this is the case, since both isoforms must be inhibited for maximal synthetic lethality. MCF-7 cells appear unusual in their extreme sensitivity to p110 α inhibition alone, however this may possibly reflect the low levels of *PIK3CB* expression in this cell line.

BEZ235 is an example of a new generation of PI3K inhibitors to enter clinical investigation in breast cancer (25). A comparison between the effects of BEZ235 and RNAi against *PIK3CA* and *PIK3CB* supports the conclusion that BEZ235 functions as a selective p110 α inhibitor at low nanomolar concentrations (25). However the apoptotic effect remained very modest in T47D cells, even at higher doses, consistent with lack of *PIK3CB* inhibition which, based on the RNAi experiments, is necessary for the full synthetic lethal effect. Estradiol suppresses BEZ235-induced apoptosis in the three ER+ cell lines, but estrogen rescue was not as dramatic as that observed in the *PIK3CA* and *PIK3CB* RNAi experiments. The reduced sensitivity to estradiol rescue likely reflects inhibition of other kinases by BEZ235.

We conclude that there is a strong rationale for the combination of endocrine therapy and PI3K inhibitors. In terms of the population of patients suitable for a clinical trial of a PI3K inhibitor combined with endocrine treatment, the data suggests that eligibility should not be restricted by *PIK3CA* mutation status. Furthermore, the association between *PIK3CA* and *PIK3CB* expression and Luminal B status indicates the addition of a PI3K inhibitor may be particularly important in more aggressive forms of ER+ disease. Finally *PIK3CB* is emerging as an important therapeutic target, whose inhibition is important not only to increase the efficacy of *PIK3CA* inhibition, but as a target in its own right, perhaps particularly in the setting of gene amplification. A combined inhibitor with low nM inhibitory properties for both *PIK3CA* and *PIK3CB* may be necessary for maximal clinical efficacy in combination with an endocrine agent in the treatment of ER+ breast cancer. However this clinical treatment strategy may be problematic since systemic inhibition of both catalytic subunits will cause derangements in insulin signaling and glucose homeostasis (16,17,39,40), and metabolic toxicity could be further enhanced by estrogen deprivation. Nonetheless it may be possible to pursue this strategy clinically because endocrine therapy in combination with a PI3 kinase inhibitor is cytotoxic. Therefore short-course high-toxicity combinations of PI3 kinase inhibitors with endocrine therapy, analogous to conventional chemotherapy, rather than prolonged exposure, may be sufficient to increase the cure rate for ER+ breast cancer.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported in part by awards from the NIH (R01 CA095614; U01 CA114722); the St. Louis Affiliate of the Susan G Komen Breast Cancer Foundation, Inc; Breast Cancer Research Foundation; and the Barnes-Jewish Hospital Research Foundation (to M.J.E). This work was also supported by awards to J.A.O. (3P50 CA68438-07S2). The Siteman Comprehensive Cancer Center is supported in part by NCI Cancer Center Support Grant #P30 CA91842.

REFERENCES

1. EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. *Lancet* 2005;365:1687–1717. [PubMed: 15894097]
2. Ellis MJ, Tao Y, Luo J, et al. Outcome Prediction for Estrogen Receptor-Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics. *JNCI* 2008;100
3. Dowsett M, Smith IE, Ebbs SR, et al. Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. *Clin Cancer Res* 2006;12:1024s–1030s. [PubMed: 16467120]
4. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. *Nat Rev Drug Discov* 2005;4:988–1004. [PubMed: 16341064]
5. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. *Science* 1997;275:1943–1947. [PubMed: 9072974]
6. Barlund M, Monni O, Kononen J, et al. Multiple genes at 17q23 undergo amplification and overexpression in breast cancer. *Cancer Res* 2000;60:5340–5344. [PubMed: 11034067]
7. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. *Science* 2004;304:554. [PubMed: 15016963]
8. Carpten JD, Faber AL, Horn C, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. *Nature* 2007;448:439–444. [PubMed: 17611497]
9. Shoman N, Klassen S, McFadden A, Bickis MG, Torlakovic E, Chibbar R. Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen. *Mod Pathol* 2005;18:250–259. [PubMed: 15475931]
10. van der Hage JA, van den Broek LJ, Legrand C, et al. Overexpression of P70 S6 kinase protein is associated with increased risk of locoregional recurrence in node-negative premenopausal early breast cancer patients. *Br J Cancer* 2004;90:1543–1550. [PubMed: 15083183]
11. Saal LH, Holm K, Maurer M, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. *Cancer Res* 2005;65:2554–2559. [PubMed: 15805248]
12. Li SY, Rong M, Grieu F, Iacopetta B. PIK3CA mutations in breast cancer are associated with poor outcome. *Breast Cancer Res Treat* 2006;96:91–95. [PubMed: 16317585]
13. Maruyama N, Miyoshi Y, Taguchi T, Tamaki Y, Monden M, Noguchi S. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. *Clin Cancer Res* 2007;13:408–414. [PubMed: 17202311]
14. Perez-Tenorio G, Alkhorri L, Olsson B, et al. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. *Clin Cancer Res* 2007;13:3577–3584. [PubMed: 17575221]
15. Barbareschi M, Buttitta F, Felicioni L, et al. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. *Clin Cancer Res* 2007;13:6064–6069. [PubMed: 17947469]
16. Ciraolo E, Iezzi M, Marone R, et al. Phosphoinositide 3-Kinase p110{beta} Activity: Key Role in Metabolism and Mammary Gland Cancer but Not Development. *Sci Signal* 2008;1:ra3. [PubMed: 18780892]
17. Jia S, Liu Z, Zhang S, et al. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. *Nature* 2008;454:776–779. [PubMed: 18594509]
18. Marone R, Cmilianovic V, Giese B, Wymann MP. Targeting phosphoinositide 3-kinase: moving towards therapy. *Biochim Biophys Acta* 2008;1784:159–185. [PubMed: 17997386]

19. Sawyer C, Sturge J, Bennett DC, et al. Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta. *Cancer Res* 2003;63:1667–1675. [PubMed: 12670921]
20. Olson JA, Budd GTLA, Carey LA, et al. Improved Surgical Outcomes for Breast Cancer Patients Receiving Neoadjuvant Aromatase Inhibitor Therapy: Results from a Multicenter II Trial. *J Am Coll Surg*. 2009 in press.
21. Brown LA, Hoog J, Chin SF, et al. ESR1 gene amplification in breast cancer: a common phenomenon? *Nat Genet* 2008;40:806–807. author reply 10–2. [PubMed: 18583964]
22. Gazdar AF, Kurvari V, Virmani A, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. *Int J Cancer* 1998;78:766–774. [PubMed: 9833771]
23. Parker JS, Mullins M, Cheang MC, et al. Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes. *J Clin Oncol*. 2009
24. Reagan-Shaw S, Ahmad N. RNA interference-mediated depletion of phosphoinositide 3-kinase activates forkhead box class O transcription factors and induces cell cycle arrest and apoptosis in breast carcinoma cells. *Cancer Res* 2006;66:1062–1069. [PubMed: 16424042]
25. Maira SM, Stauffer F, Brueggen J, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. *Mol Cancer Ther* 2008;7:1851–1863. [PubMed: 18606717]
26. Kyprianou N, English HF, Davidson NE, Isaacs JT. Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. *Cancer Res* 1991;51:162–166. [PubMed: 1899037]
27. Warri AM, Huovinen RL, Laine AM, Martikainen PM, Harkonen PL. Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro. *J Natl Cancer Inst* 1993;85:1412–1418. [PubMed: 8350365]
28. Detre S, Salter J, Barnes DM, et al. Time-related effects of estrogen withdrawal on proliferation- and cell death-related events in MCF-7 xenografts. *Int J Cancer* 1999;81:309–313. [PubMed: 10188736]
29. Dowsett M, Smith IE, Ebbs SR, et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. *Clin Cancer Res* 2005;11:951s–958s. [PubMed: 15701892]
30. Migliaccio A, Di Domenico M, Castoria G, et al. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. *Embo J* 1996;15:1292–1300. [PubMed: 8635462]
31. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. *Nature* 2000;407:538–541. [PubMed: 11029009]
32. Zhao JJ, Liu Z, Wang L, Shin E, Loda MF, Roberts TM. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. *Proc Natl Acad Sci U S A* 2005;102:18443–18448. [PubMed: 16339315]
33. Isakoff SJ, Engelman JA, Irie HY, et al. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. *Cancer Res* 2005;65:10992–11000. [PubMed: 16322248]
34. Zhao JJ, Cheng H, Jia S, et al. The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. *Proc Natl Acad Sci U S A* 2006;103:16296–16300. [PubMed: 17060635]
35. Czauderna F, Fechtner M, Aygun H, et al. Functional studies of the PI(3)-kinase signalling pathway employing synthetic and expressed siRNA. *Nucleic Acids Res* 2003;31:670–682. [PubMed: 12527776]
36. Pu P, Kang C, Zhang Z, Liu X, Jiang H. Downregulation of PIK3CB by siRNA suppresses malignant glioma cell growth in vitro and in vivo. *Technol Cancer Res Treat* 2006;5:271–280. [PubMed: 16700623]
37. An HJ, Cho NH, Yang HS, et al. Targeted RNA interference of phosphatidylinositol 3-kinase p110-beta induces apoptosis and proliferation arrest in endometrial carcinoma cells. *J Pathol* 2007;212:161–169. [PubMed: 17427168]
38. Kim MS, Jeong EG, Yoo NJ, Lee SH. Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. *Br J Cancer* 2008;98:1533–1535. [PubMed: 18392055]

39. Knight ZA, Gonzalez B, Feldman ME, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. *Cell* 2006;125:733–747. [PubMed: 16647110]
40. Foukas LC, Claret M, Pearce W, et al. Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. *Nature* 2006;441:366–370. [PubMed: 16625210]




Figure 1. *PIK3CB* is amplified in breast cancer

A, p110 α and p110 β expression in breast cancer cell lines. Equal amounts (25 μ g) of protein from each cell line were immunoblotted for the indicated proteins. Longer exposures revealed that both p110 α and p110 β proteins were expressed in all cell lines. B, *PIK3CB* aCGH analysis in breast cancer cell lines. Shown is a section of probes on chromosome 3 corresponding to the *PIK3CB* locus. Individual array probes indicate probable copy number gain (red), loss (green), or no change (gray) relative to female diploid DNA. C, aCGH and *PIK3CB* FISH in ER+ breast tumors. Top panel, aCGH probes corresponding to the *PIK3CB* locus. Arrows indicate tumor samples subjected to *PIK3CB* FISH. One of the FISH-tested tumor samples (*)

contained *PIK3CB* amplification. Bottom panel, FISH results from the *PIK3CB*-amplified breast tumor above. The CEP3 probe is red; the *PIK3CB*-specific probe is green.




Figure 2. p110 α is the predominant mediator of PI3K signaling in breast cancer cells

A, effect of p110 α and p110 β knockdown on PI3K signaling. Cells were transfected with control siRNAs (*Control*) or siRNAs against *PIK3CB* (*PIK3CB*) or *PIK3CA* (*PIK3CA*). Three days after transfection, serum-deprived cells were stimulated with 20% FBS (final concentration) and lysates were analyzed for effects on PI3K pathway signaling through phospho-Akt (*p-Akt*) and phospho-S6 (*p-S6*) immunoblotting. Shown are representative immunoblots obtained from at least three experiments per cell line. **B**, effect of p110 α /p110 β dual knockdown on PI3K signaling. Cells were transfected with control siRNAs or a mixture of *PIK3CA* and *PIK3CB* siRNAs (*CA/CB*), treated as above and subjected to immunoblot analysis. Representative results obtained in at least two experiments per cell line are shown.




Figure 3. *PIK3CA* and *PIK3CB* RNAi cause synthetic lethality in estrogen-deprived ER+ breast cancer cells

A, *PIK3CA* and *PIK3CB* RNAi inhibit growth of ER+ breast cancer cells. Cells in CSS medium were transfected with 10 nM Control (*si Control*), *PIK3CB* (*si PIK3CB*) or *PIK3CA* (*si PIK3CA*) siRNAs. Cells were treated without (–E2) or with 10 nM estradiol (+E2) in the absence or presence of 300 nM Fulvestrant (*Fulv*) or 20 μM LY294002 (*LY*). Growth was assessed after 10 d of treatment and is expressed relative to untreated (–E2), Control siRNA transfected cells. Results from five experiments per cell line are shown. Significant differences ($p < 0.05$, *) between treatments in *PIK3CB* or *PIK3CA* siRNA transfected cells and identical treatments in Control siRNA transfected cells are indicated. *B*, *PIK3CA* and *PIK3CB* RNAi

promote apoptosis in estrogen-deprived ER+ cells. Cells growing in CSS medium were transfected with siRNAs as in A, above and treated without or with 10 nM estradiol for 7d. Apoptosis was assessed by counting TUNEL-positive or pyknotic Hoechst-stained nuclei. Results from four experiments per cell line are shown. Significant differences ($p < 0.05$. *) between estrogen-deprived Control siRNA and estrogen-deprived *PIK3CB* or *PIK3CA* siRNA transfected cells are indicated. Estrogen suppression of *PIK3CB* RNAi-induced apoptosis in HCC712 cells was not statistically significant ($p = 0.06$).




Figure 4. Dual *PIK3CA/PIK3CB* RNAi enhances apoptosis in estrogen-deprived ER+ cells

A, dual *PIK3CA/PIK3CB* RNAi inhibits growth of ER+ cells. Cells in CSS medium were transfected with 20 nM Control (*si Control*) or 10 nM each (20 nM final) *PIK3CA* and *PIK3CB* siRNAs (*si CA/CB*). Cells were left untreated or treated with 10 nM estradiol (*E2*) and growth was assessed after 10d. Growth is expressed relative to untreated, Control siRNA transfected cells. Results are from 4–6 experiments per cell line. Significant differences ($p < 0.05$, *) between Control siRNA and *PIK3CA/PIK3CB* siRNA transfected cells in the presence or absence of estradiol are indicated. **B**, dual p110 α /p110 β knockdown enhances apoptosis in ER+ cells. Cells were transfected with 20 nM Control or 10 nM each *PIK3CA* and *PIK3CB* siRNAs. Cells were left untreated or treated with 10 nM estradiol for 7d and apoptosis was

assessed by counting Hoechst-stained nuclei. Results from four experiments per cell line are shown. Significant differences ($p < 0.05$, *) between Control siRNA and dual *PIK3CA/PIK3CA* siRNA transfected cells in either the presence or absence of estradiol are indicated. Estradiol significantly suppressed *PIK3CA/PIK3CB* RNAi-induced apoptosis MCF-7, T47D and HCC712 cells. C, dual p110 α /p110 β knockdown was performed in T47D cells with alternative *PIK3CA* and *PIK3CB* siRNAs. Cells were left untreated, treated with 10 nM estradiol or treated with estradiol + 300 nM Fulvestrant (*Fulv*) for 7d. Apoptosis was assessed by counting Hoechst-stained nuclei. Results from four experiments are shown. Significant differences ($p < 0.05$, *) between Control and *PIK3CA/PIK3CA* siRNA transfected cells in either the presence or absence of estradiol are indicated.




Figure 5. BEZ235 causes synthetic lethality in estrogen-deprived ER+ breast cancer cells

A, BEZ235 treatment inhibits PI3K pathway signaling in breast cancer cells. Serum-starved cells were treated with vehicle (DMSO), the indicated concentrations of BEZ235, LY294002 (20 μM), or rapamycin (100 nM) then stimulated with 20% FBS. Cell lysates were immunoblotted to determine effects on PI3K signaling by phospho-Akt (*p-Akt*) and phospho-S6 (*p-S6*) antibodies and on MAPK signaling via phospho-ERK (*p-ERK 1/2*) antibodies. Shown are representative results from at least two experiments per cell line. **B**, BEZ235 inhibits growth of breast cancer cells. Cells in CSS medium were treated without or with BEZ235 in the absence or presence of 10 nM estradiol (*E2*). Cell growth was measured after 10 d and is calculated relative to growth in untreated (-*E2*) cells. Shown are results from five experiments

per cell line. Significant differences in growth between estrogen-deprived and estrogen-deprived, drug-treated cells are indicated ($p < 0.05$, *). Significant differences in growth between estrogen-stimulated and estrogen-stimulated cells, drug-treated cells are indicated ($p < 0.05$, #). C, BEZ235 promotes apoptosis in ER+ cells. Cells growing in CSS medium were treated with the indicated concentrations of BEZ235 without or with 10 nM estradiol for 7d. Apoptosis was assessed by counting Hoechst-stained nuclei. Results from 4–6 experiments per cell line are shown. Significant induction of cell death in estrogen-deprived, BEZ235 treated cells ($p < 0.05$, *) and cells treated with BEZ235 in the presence of estradiol ($p < 0.05$, #) is indicated.

Table 1
***PIK3CA*, *PIK3CB* and *PIK3CD* Expression in Relation to ER+ Breast Cancer Subtype and *PIK3CA* Mutation Status**

Gene expression in primary breast tumors was measured by whole genome expression arrays and ER+ tumors were subtyped by PAM50 subclassification to Luminal A (*LumA*) and Luminal B (*LumB*) and *PIK3CA* mutation status was determined. Means and standard deviations (in parenthesis) were calculated for subtypes and mutation status. The 95% confidence intervals (CI) were calculated for the mean difference of LumB to LumA and *PIK3CA* mutant to wild-type. Two-sample t-tests were used to determine differences in the expression of *PIK3CA*, *PIK3CB* and *PIK3CD* based on LumB versus LumA subtypes and *PIK3CA* mutant (*MUT*) versus *PIK3CA* wild-type (*WT*) tumors.

	Expression Mean (SD)	95% CI for mean difference	P-Value
<i>PIK3CA</i> Expression			
LumB	0.41 (0.42)	0.11 ~ 0.54	0.003
LumA	0.08 (0.50)		
<i>PIK3CA</i> MUT	0.45 (0.47)	0.04 ~ 0.49	0.02
<i>PIK3CA</i> WT	0.18 (0.47)		
<i>PIK3CB</i> Expression			
LumB	-0.31 (0.46)	0.14 ~ 0.66	0.005
LumA	-0.72 (0.66)		
<i>PIK3CA</i> MUT	-0.41 (0.59)	-0.16 ~ 0.41	0.37
<i>PIK3CA</i> WT	-0.53 (0.58)		
<i>PIK3CD</i> Expression			
LumB	-0.1 (0.16)	-0.16 ~ -0.01	0.03
LumA	-0.01 (0.16)		
<i>PIK3CA</i> MUT	-0.09 (0.16)	-0.13 ~ 0.03	0.25
<i>PIK3CA</i> WT	-0.05 (0.17)		